Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trial One-third enrollment complete in cohort of patients with metastatic cutaneous squamous cell carcinoma Potential for cosibelimab to be differentiated and lower-cost alternative to available anti-PD-1/L1 mAbs

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here